How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?

AbbVie's Q2 results exceeded expectations, primarily driven by robust sales of its immunology drugs Skyrizi and Rinvoq, which grew 62% to $4.42 billion and 41% to $2.03 billion respectively, effectively mitigating Humira's continued erosion. The company raised its 2025 Skyrizi sales guidance to $17.1 billion and projects combined sales for Skyrizi and Rinvoq to surpass $25 billion in 2025, signaling a successful post-Humira transition and an anticipated return to growth despite a reduced U.S. Humira revenue outlook due to increased biosimilar competition.

Analysis

AbbVie's second-quarter 2025 results signal a successful and accelerated transition beyond its former blockbuster, Humira. The company's newer immunology drugs, Skyrizi and Rinvoq, are demonstrating significant commercial strength, with year-over-year operational sales growth of 62% to $4.42 billion and 41% to $2.03 billion, respectively. This performance, driven by strong market share gains in key indications like inflammatory bowel disease (IBD), has prompted management to raise its full-year 2025 sales guidance for Skyrizi by $600 million to $17.1 billion. This upward revision more than offsets the increased erosion of Humira, whose U.S. revenue forecast was cut by $500 million to $3 billion due to intensifying biosimilar competition. The combined sales of Skyrizi and Rinvoq are now projected to surpass $25 billion in 2025, reinforcing AbbVie's expectation to return to top-line growth that year. Despite this positive operational momentum and outperformance relative to its industry year-to-date, the stock trades at a slight premium with a forward P/E of 14.58 versus the industry's 14.28, and analyst estimates for future earnings have been mixed, suggesting the market has already priced in much of this success.

Key Decisions for Investors

• Investors should view the strong uptake of Skyrizi and Rinvoq as a significant de-risking event for AbbVie's post-Humira growth narrative, potentially justifying the stock's current premium valuation.
• Given the stock's outperformance and valuation above its five-year mean, it may be prudent to monitor for any market pullbacks to establish or add to positions at more attractive entry points.
• Closely track the competitive landscape, particularly the commercial performance of Johnson & Johnson's Tremfya and Eli Lilly's Omvoh, as their success in the immunology space represents the primary risk to AbbVie's projected market share and long-term growth.
• While the growth story is compelling, investors should monitor the rate of Humira's sales erosion to ensure it does not accelerate beyond the newly lowered guidance, as this remains a material headwind to near-term financials.